PDS Biotechnology Corp
PDSB0.715USD
+0.025+3.59%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
34.11MMarket Cap
LossP/E TTM
More Details of PDS Biotechnology Corp Company
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
PDS Biotechnology Corp Info
Ticker SymbolPDSB
Company namePDS Biotechnology Corp
IPO dateOct 01, 2015
CEOBedu-Addo (Frank)
Number of employees24
Security typeOrdinary Share
Fiscal year-endOct 01
Address303A College Road East
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone18002083343
Websitehttps://www.pdsbiotech.com
Ticker SymbolPDSB
IPO dateOct 01, 2015
CEOBedu-Addo (Frank)
Company Executives of PDS Biotechnology Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
--
--
Mr. Spencer Brown
Mr. Spencer Brown
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
Senior Vice President, Compliance Officer, General Counsel, Corporate Secretary
--
--
Mr. Lars Boesgaard
Mr. Lars Boesgaard
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer and Principal Financial Officer
--
--
Dr. Kirk V. Shepard, M.D.
Dr. Kirk V. Shepard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank Bedu-Addo, Ph.D.
Dr. Frank Bedu-Addo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
690.87K
--
Mr. Stephen C. (Steve) Glover
Mr. Stephen C. (Steve) Glover
Independent Chairman of the Board
Independent Chairman of the Board
78.85K
--
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Mr. Gregory Gene (Greg) Freitag, CPA., J.D.
Independent Director
Independent Director
61.21K
--
Ms. Kamil Ali-Jackson, Esq., J.D.
Ms. Kamil Ali-Jackson, Esq., J.D.
Independent Director
Independent Director
11.76K
--
Dr. Gregory L. Conn, Ph.D.
Dr. Gregory L. Conn, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ilian Petkov Iliev
Dr. Ilian Petkov Iliev
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Other
92.22%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.73%
Bedu-Addo (Frank)
1.32%
BlackRock Institutional Trust Company, N.A.
0.97%
Geode Capital Management, L.L.C.
0.92%
Sykes (Richard)
0.85%
Other
92.22%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.56%
Individual Investor
2.69%
Investment Advisor/Hedge Fund
2.12%
Hedge Fund
1.29%
Research Firm
0.65%
Venture Capital
0.04%
Other
86.65%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
172
5.60M
10.70%
-4.10M
2025Q3
178
7.65M
16.41%
-3.65M
2025Q2
188
9.63M
21.07%
+1.19M
2025Q1
201
9.77M
22.08%
+1.54M
2024Q4
205
5.67M
12.73%
-3.40M
2024Q3
205
5.76M
15.58%
-3.85M
2024Q2
208
6.94M
18.83%
-4.50M
2024Q1
195
8.96M
25.12%
-3.13M
2023Q4
194
9.68M
31.15%
-1.91M
2023Q3
192
9.20M
29.70%
-3.29M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
1.90M
3.63%
-49.90K
-2.56%
Sep 30, 2025
Bedu-Addo (Frank)
690.87K
1.32%
--
--
Apr 17, 2025
BlackRock Institutional Trust Company, N.A.
508.21K
0.97%
+3.13K
+0.62%
Sep 30, 2025
Geode Capital Management, L.L.C.
482.00K
0.92%
+64.06K
+15.33%
Sep 30, 2025
Sykes (Richard)
445.11K
0.85%
--
--
Apr 17, 2025
Citadel Advisors LLC
386.43K
0.74%
+137.41K
+55.18%
Sep 30, 2025
Squarepoint Capital LLP
291.63K
0.56%
+193.86K
+198.29%
Sep 30, 2025
Renaissance Technologies LLC
275.86K
0.53%
+170.17K
+161.02%
Sep 30, 2025
UBS Financial Services, Inc.
86.26K
0.16%
-337.96K
-79.67%
Sep 30, 2025
William Blair & Company, L.L.C. (Research)
250.00K
0.48%
--
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Invesco NASDAQ Future Gen 200 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
